Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Oral presentation

Postnatal Syk deletion in mice clarifies the function of Syk in an anti-collagen antibody-induced arthritis model

Authors: Naoko Ozaki, Shinobu Suzuki, Hiromitsu Hara, Hiroki Yoshida

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

Spleen tyrosine kinase (Syk) is a cytoplasmic protein expressed mainly in immune cells including macrophages and neutrophils and is associated with receptors containing an immunoreceptor tyrosine-based activation motif (ITAM), such as Fcγ receptors. As Syk-mediated signaling plays an important role in activation of immune responses, to investigate whether specific interruption of Syk-mediated signaling can affect the development of rheumatoid arthritis (RA), we used tamoxifen-induced conditional Syk-KO mice (iSyk KO) to evaluate the importance of Syk on disease development. Using a collagen antibody-induced arthritis model (CAIA), iSyk KO mice showed significantly attenuated disease severity compared to Syk non-deleted mice (Figure 1). Although iSyk KO mice contained reduced B cell numbers after deletion of Syk in adulthood, B cells are not required for arthritis development in CAIA, as demonstrated by using muMT mice which lack B cells. On the other hand, Syk-deficient macrophages produced less MCP-1 and IL-6 than Syk-sufficient cells after FcR ligation, which can account for the absence of a pronounced accumulation of neutrophils and macrophages in the joints of iSyk KO mice. Our results demonstrate that Syk in macrophages is likely a key player in antibody-induced arthritis, mediating the release of pro-inflammatory cytokines and chemokines after macrophages bind anti-collagen antibody, and indicate that Syk is a promising target for arthritis therapy.
Metadata
Title
Postnatal Syk deletion in mice clarifies the function of Syk in an anti-collagen antibody-induced arthritis model
Authors
Naoko Ozaki
Shinobu Suzuki
Hiromitsu Hara
Hiroki Yoshida
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3577

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.